Acuta Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.66M Buy
535,109
+27,308
+5% +$355K 5.82% 4
2026
Q2
$6.75M Buy
+507,801
New +$4.95M 4.71% 6
2024
Q1
– Sell
-74,500
Closed -$1.51M – 40
2023
Q4
$1.51M Buy
+74,500
New +$980K 0.85% 29
2023
Q2
– Sell
-104,753
Closed -$1.8M – 36
2023
Q1
$1.8M Buy
+104,753
New +$2.04M 1.33% 20
2021
Q2
– Sell
-20,000
Closed -$868K – 43
2021
Q1
$868K Hold
20,000
– – 0.31% 42
2020
Q4
$829K Buy
+20,000
New +$826K 0.23% 46

Other funds holding FDMT

Acuta Capital Partners's FDMT Position: Q3 2026 in Review

Acuta Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 5.4% in Q3 2026, buying an estimated $355K and bringing the position to 535,109 shares worth $7.66M. The position accounts for 5.82% of the portfolio, ranked #4.

Acuta Capital Partners first reported a position in FDMT in Q4 2020 and has held it in 6 quarters since. 166 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Acuta Capital Partners held 535,109 shares of 4D Molecular Therapeutics worth $7.66M as of Q3 2026.
  • Acuta Capital Partners bought 27,308 4D Molecular Therapeutics shares in Q3 2026, an estimated $355K.
  • 4D Molecular Therapeutics made up 5.82% of Acuta Capital Partners's portfolio in Q3 2026, its #4 holding.
  • Acuta Capital Partners first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • 166 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.